drugset
drugset / Trial / NCT04783636

To Compare the Safety and Pharmacokinetics of PT105 With PT105R in Healthy Postmenopausal Female Volunteers

NCT04783636 ↗

Phase 1 Unknown 40 enrolled Peptron, Inc.
RandomizedCrossoverDouble-blindTreatment

Summary

The purpose of study is to compare the safety and pharmacokinetics of PT105 with PT105R in healthy postmenopausal female volunteers

Timeline

Start
2021-03-11
Primary completion
2021-07-20
Completion
2021-07-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Leuprolide Other / unclassified 3.75 mg —

Indications

prostate cancer